Johnson & Johnson Receives FDA Clearance for Surgical Robot and Targets $100 Billion in Revenue
Johnson & Johnson (NYSE: JNJ) is experiencing strong performance this year, with its shares up 28% compared to the S&P 500's 8%. The company reported a 6.6% increase in second-quarter net sales and remains on track for over $100 billion in annual revenue—a historic milestone for biopharmaceutical firms. The healthcare giant recently received FDA clearance for its Ottava robotic-assisted surgery system, positioning itself to enter the growing RAS market. Additionally, Johnson & Johnson has raised its dividend for 64 consecutive years and is now a Dividend King. Perhaps most notably, J&J may be close to resolving long-standing talc-related lawsuits with a proposed $5.5 billion settlement over two years. This would remove a major reputational and financial risk from the company's books.
Tickers: $JNJ
Topics: dividend growth Johnson & Johnson lawsuits robotic surgery